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Background: Endometrial stromal sarcomas (ESSs) are rare, indolent tumorswith high recurrence rates.Manage-
ment includes surgery andhormonal therapy given high estrogen and progesterone receptor (ER/PR) expression.
Case:A pre-menopausal patientwith stage II ESSs (ER+/PR+)underwent primary surgery followed by adjuvant
megestrol. Recurrence in the bladder/upper vagina (ER+/PR−) was diagnosed one year later and treated with
anterior pelvic exenteration and adjuvant letrozole. Two years later she recurred and was treated with radical
surgery and adjuvant exemestane therapy (tumor ER strongly +/PR+). The patient then had a ﬁve-year disease
free interval before being diagnosed with her third recurrence (ER+).
Conclusion: Exemestane treatment for ESSs can lead to a prolonged response, even in the setting of progression
after prior aromatase inhibitor treatment.Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Endometrial stromal tumors represent a spectrum of histologies
ranging from benign to malignant lesions. Based on the 2003 World
Health Organization (WHO) guidelines, cytologic differentiation and
lymphovascular/myometrial invasion are used to classify endometrial
stromal tumors into three general categories: endometrial stromal nod-
ule (ESN), a benign lesion, endometrial stromal sarcoma (ESS), a low-
grade lesion, and undifferentiated endometrial sarcoma (UES), a frankly
malignant lesion (Yoon et al., 2014). Historically, ESS was distinguished
as either low-grade or high-grade; however, high-grade lesions are now
considered UES (Yoon et al., 2014). ESS, in particular, is rare and com-
prises approximately 0.2% of all uterine cancers and 10–25% of all uter-
ine sarcomas (Yoon et al., 2014; Rauh-Hain and del Carmen, 2013;
El-Khalfaoui et al., 2014).
Thoughmuch of the data on ESS is based on small studies and case se-
ries, it is generally considered to be an indolent tumor that is resistant to
chemotherapy yet prone to recurrence. Patients with ESS, however, have
a better overall survival when compared to patients with other uterine
sarcomas (El-Khalfaoui et al., 2014). Hysterectomy with bilateral oopho-
rectomy is the cornerstone of treatment for early stage disease; the role
of lymphadenectomy remains controversial. In young women with
early stage disease, ovarian conservation may be an option (Rauh-Hainary Medical Center Department
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ss article under the CC BY-NC-ND licand del Carmen, 2013). ESS typically demonstrates an over-expression
of estrogen (ER) and progesterone receptors (PR) (Rauh-Hain and del
Carmen, 2013). Adjuvant hormonal treatment has been shown to reduce
the risk of recurrence when used in patients with advanced stage disease
aswell as improved clinical outcomes in the setting of recurrence, howev-
er, data is currently lacking on the use of adjuvant hormonal therapy for
early stage disease (Rauh-Hain and del Carmen, 2013; Amant et al.,
2007; Sommeijer and Sjoquist, 2013; Mizuno et al., 2012).
Adjuvant hormonal therapy options include megestrol or
medroxyprogesterone, gonadotropin releasing hormone analogs
(GnRHs), and aromatase inhibitors (AIs). Exemestane, a type 1 steroidal
irreversible AI, is well tolerated and has shown clinical beneﬁt for hor-
monally sensitive tumors (Lindemann et al., 2014; Thanopoulou et al.,
2014). Exemestane has been used most commonly in the setting of
breast cancer treatment or chemoprevention, but has also been used
in endometrial carcinoma and leiomyosarcoma (Lindemann et al.,
2014; Thanopoulou et al., 2014; Dunn et al., 2013; Bliss et al., 2012).
There is no current consensus on the optimal adjuvant hormonal
therapy for recurrent ESSs. We present a case of a prolonged response
to exemestane therapy in a patient with multiple recurrences of ESSs.2. Case
A premenopausal patient with a benign pre-operative endometrial
biopsy underwent a total abdominal hysterectomy and left salpingo-
oophorectomy for menorrhagia. The uterus was found to have an ESSense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 2. CT scan showing large soft tissue mass ﬁlling and distending the right atrium.
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underwent a right salpingo-oophorectomy and pelvic lymph node dis-
sectionwith ﬁnal pathology demonstrating a stage IIB endometrial stro-
mal sarcoma (ER+/PR+). The patient was then started on adjuvant
megestrol therapy.
One year later the patient presented with hematuria. Imaging stud-
ies demonstrated bladder and endovaginal masses. She underwent a
supralevator anterior pelvic exenteration with ileal conduit urinary di-
version. Final pathology demonstrated ESS (ER+/PR-), and she was
treated with adjuvant letrozole.
Two years after the exenteration, a surveillance CT scandemonstrated
an intravascular mass extending from the common iliac veins cephalad
into the right atrium and ventricle (Figs. 1 and 2). The patient then
underwent a multidisciplinary procedure with cardiothoracic surgery,
vascular surgery, and urology. A median sternotomy and laparotomy
was performed for exposure, and full cardiopulmonary bypass with
deep hypothermic circulatory arrest (DHCA, 18°°C)was employed for ap-
proximately 30min to allow removal of the intracardiac and retrohepatic
tumor. During rewarming after the DHCA, the infrarenal IVC and left iliac
system was opened longitudinally to remove the tumor. The abdominal
portion of the sarcomawas N20 cm long and nearly obliterated the entire
left iliac and IVC lumens. The pathology from the specimens revealed ESS
(ER strongly +/PR +). The patient then began adjuvant exemestane
therapy.
The patient remained disease-free for ﬁve years until routine sur-
veillance imaging showed evidence of recurrence with masses in her
ileal conduit and peritoneal cavity. She underwent an exploratory lapa-
rotomy, debulking, small bowel resection, and resection of the ileal con-
duit with creation of a new ileal conduit. The pathology was consistent
with ESS recurrence (ER+). Her hormonal therapy was changed to
anastrozole, which she continues today.3. Discussion
Endometrial stromal sarcomas are the least common type of uterine
neoplasm.Much of the current data on treatmentmanagement is limit-
ed to small case series. The mainstay for early stage disease consists of
hysterectomy and bilateral oophorectomy. Adjuvant treatment usually
consists of indeﬁnite hormonal therapy as these indolent tumors are
typically ER/PR positive. Adjuvant treatment with chemotherapy or ra-
diation is not routinely recommended unless hormonal therapies have
become ineffective (Amant et al., 2014).
Given the high rate of ER/PR expression in ESSs, reported as high as
100%, hormonal therapy has been advocated as ﬁrst line treatment
(Amant et al., 2014). Hormonal therapies used in the treatment of
ESSs include megestrol or medroxyprogesterone, the GnRHs and theFig. 1. CT scan demonstrating near-complete occlusion and marked distention of inferior
vena cava.AIs. There is little objective data on the most effective hormonal treat-
ment regimen, dose, and duration of therapy.
Aromatase inhibitors have shown clinical beneﬁt in ESSs although
data is limited to case reports and small case series. Aromatase inhibitors
block the synthesis of estrogen in peripheral adipose tissue, and directly
inhibit aromatase activity in tumor tissue (Thanopoulou et al., 2014).
There are two categories of AIs based on their chemical structure: type I
AIs are steroidal inhibitors and bind aromatase irreversibly by covalent
bonds, while type II AIs are nonsteroidal inhibitors that bind reversibly
and covalently with aromatase (Chan and Fan, 2013). Exemestane is a
type I AI whereas letrozole and anastrozole are type II AIs. Much of the
knowledge gained from the clinical beneﬁt of aromatase inhibitors
comes from its use in breast cancer, however, there is little data compar-
ing the two classes of AIs as there has been no head-to-head comparison
of the two classes. Anastrozole, letrozole, and exemestane have all been
shown to suppress estrogen by greater than 97%, however, potentially
small variations in the level of estrogen suppression between the two
classes of AIs may have some biological importance in length of response
to one class versus the other (Dowsett, 1999). Additionally biologically
signiﬁcant differences in estrogen concentrationswith treatment are like-
ly below the threshold of standard immunoassay detection methods at
present, and difﬁcult to conﬁrm as a result (Dowsett, 1999). Given the
rarity of ESSs, the results from letrozole and anastrozole treatment have
often been reported together, and both have demonstrated clinical
beneﬁts when used in hormone receptor positive uterine cancers
(Thanopoulou et al., 2014). One small retrospective case series reported
an overall response rate of 67% (60% partial response rate, 7% complete
response rate), and a 20% stable disease rate in 16 patientswith ESS treat-
ed with AIs (Altman et al., 2012). Additionally, these medications have
demonstrated a lack of complete cross-resistance to each other when
used to treat hormonally sensitive breast cancer though the etiology of
this phenomenon has yet to be found (Lønning, 2009).
Treatment of ESS with exemestane has only been reported twice
previously (Dowsett, 1999; Klaritsch et al., 2006); our case further dem-
onstrates the therapeutic potential of exemestane for ESSs. Our patient
with multiple ESS recurrences was without evidence of disease for
5 years with exemestane therapy. This case highlights two points re-
garding treatment of ESSs. First,when surgically feasible, resection of re-
current disease should be considered. This patient underwent three
radical procedures over the 10 years since her original diagnosis, with
each surgery resulting in complete resection. Each recurrence proved
to be in a different location than the last, and this further emphasizes
the effectiveness of surgery. The second point highlights the importance
of continuing different AI therapy despite failure of prior AIs in tumors
that are ER+. Whether radical debulking surgeries or the use of hor-
monal therapy contributes to better outcomes is unknown, however,
it is plausible that a combination of both is necessary for a durable
6 H. Wolfe et al. / Gynecologic Oncology Reports 15 (2016) 4–6response. As third-line therapy, it is notable that the patient experi-
enced a ﬁve-year disease-free interval when using exemestane while
prior hormonal treatments yielded 1–2 years. The lack of cross-
resistance between different AIs allows an additional therapeutic win-
dow for treatment of ESSs with this class of medications. Although con-
sidered indolent, recurrent ESSs can be a challenging disease to treat
requiring multidisciplinary surgical procedures and multiple hormonal
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